EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals

Sandra Aleksic iD, Eric Lontchi-Yimagou, William Mitchell, Caroline Boyle, Priyanka Matias, Anjali Manavalan, Akankasha Goyal, Michelle Carey, Ilan Gabriely, Meredith Hawkins iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae479 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Sandra Aleksic und 9 weiteren Autor:innen. Beteiligte Einrichtung: Albert Einstein College of Medicine, Bronx, NY 10461, USA. Hauptthemen laut MEDLINE: Naloxone, Hypoglycemia, Narcotic Antagonists, Autonomic Nervous System Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Center for Advancing Translational Science Einstein-Montefiore Clinical and Translational Science Awards, American Diabetes Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Hypoglycemia-associated autonomic failure (HAAF), defined as blunting of counterregulatory hormone and symptom responses to recurrent hypoglycemia, remains a therapeutic challenge in diabetes treatment. The opioid system may play a role in HAAF pathogenesis since activation of opioid receptors induces HAAF. Blockade of opioid receptors with intravenous naloxone ameliorates HAAF experimentally yet is not feasible therapeutically.

Objective

To investigate the effects of opioid receptor blockade with intranasal naloxone on experimentally induced HAAF.

Design

Randomized, double-blinded, placebo-controlled crossover study.

Setting

Academic research center.

Participants

Healthy nondiabetic volunteers.

Interventions

Paired 2-day studies, 5 to 10 weeks apart, each consisting of 3 consecutive hypoglycemic episodes (hyperinsulinemic hypoglycemic clamps, glucose nadir: 54 mg/dL): 2 on day 1 with administration of intranasal naloxone vs placebo, followed by the third episode on day 2. Main Outcome Measures Differences in counterregulatory hormones responses and hypoglycemia symptoms between first and third hypoglycemic episodes in naloxone vs placebo studies.

Results

Out of 17 participants, 9 developed HAAF, confirming variable interindividual susceptibility. Among participants susceptible to HAAF, naloxone maintained some hormonal and symptomatic responses to hypoglycemia and prevented the associated requirement for increased glucose infusion. Unexpectedly, naloxone reduced plasma epinephrine and GH responses to the first hypoglycemic episode but prevented further reduction with subsequent hypoglycemia.

Conclusion

This is the first study to report that intranasal naloxone, a widely used opioid receptor antagonist, may ameliorate some features of HAAF. Further investigation is warranted into mechanisms of variable interindividual susceptibility to HAAF and the effects of intranasal naloxone in people with diabetes at risk for HAAF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaloxoneHypoglycemiaNarcotic AntagonistsAutonomic Nervous System DiseasesHumansAdministration, IntranasalCross-Over StudiesDouble-Blind MethodMaleFemaleAdultBlood GlucoseYoung AdultEpinephrineMiddle AgedDisease Susceptibility

Stichwörter der Autor:innen

HAAFcounterregulatory responseshypoglycemiahypoglycemia unawarenesshypoglycemia-associated autonomic failureintranasal naloxoneopioid receptors

Substanzen

NaloxoneNarcotic AntagonistsBlood GlucoseEpinephrine

Autor:innen und Institutionen

  • Albert Einstein College of Medicine, Bronx, NY 10461, USA.
  • New York University Langone Medical Center, New York, NY 10017, USA.
  • Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20903, USA.

ORCID-Profile: Sandra Aleksic, Meredith Hawkins

Förderung

  • NIDDK NIH HHS
  • National Center for Advancing Translational Science Einstein-Montefiore Clinical and Translational Science Awards
  • American Diabetes Association
  • NCATS NIH HHS
  • Einstein-Mount Sinai Diabetes Research Center
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Aleksic, S., Lontchi-Yimagou, E., Mitchell, W., Boyle, C., Matias, P., Manavalan, A., Goyal, A., Carey, M., Gabriely, I., & Hawkins, M. (2025). Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae479

Vancouver

Aleksic S, Lontchi-Yimagou E, Mitchell W, Boyle C, Matias P, Manavalan A, et al. Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae479

BibTeX
@article{Aleksic2025,
  author = {Aleksic, Sandra and Lontchi-Yimagou, Eric and Mitchell, William and Boyle, Caroline and Matias, Priyanka and Manavalan, Anjali and Goyal, Akankasha and Carey, Michelle and Gabriely, Ilan and Hawkins, Meredith},
  title = {Effects of Intranasal Naloxone on Hypoglycemia-associated Autonomic Failure in Susceptible Individuals},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae479}
}
Kostenlos starten →